Minimal Residual Disease Pipeline Set for Strategic Expansion by 2026 with Emerging Immunotherapies and Precision Diagnostics
核心洞察
The Minimal Residual Disease (搜索) pipeline features over five therapeutic candidates from companies including Genentech, AmMax Bio (搜索), and Precigen Inc (搜索), spanning multiple clinical stages.
Immunotherapy-based approaches such as monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies are at the forefront of MRD-directed innovation.
The FDA released draft guidance in January 2026 regarding MRD and complete response as primary endpoints for accelerated approval in multiple myeloma trials.
The Minimal Residual Disease (搜索) (MRD) pipeline is undergoing a transformative shift, driven by advancements in immunotherapy, targeted therapies, and molecular diagnostics. According to DelveInsight's "Minimal Residual Disease Pipeline Insight, 2026" report, approximately five companies are actively engaged in developing MRD-focused therapies, collectively advancing over five pipeline candidates across various stages of clinical development. Key players including Genentech, AmMax Bio (搜索), and Precigen Inc (搜索) are leveraging cutting-edge platforms to target residual disease with high precision, reflecting the growing recognition of MRD as a critical determinant of long-term cancer outcomes.
Regulatory Momentum: FDA Draft Guidance on MRD Endpoints
On January 20, 2026, the U.S. Food and Drug Administration (FDA) released a draft guidance for industry regarding the use of minimal residual disease (搜索) and complete response as primary endpoints in clinical trials evaluating drugs and biologics for the treatment of patients with multiple myeloma that would support accelerated approval. This regulatory development signals a significant shift in how MRD is being integrated into oncology drug development, potentially reshaping clinical trial design and accelerating the path to market for novel therapies.
Diagnostic Innovation Driving MRD Detection
Advancements in molecular diagnostics have significantly enhanced the ability to detect MRD with high sensitivity. Techniques such as multiparametric flow cytometry, polymerase chain reaction (PCR)-based methods including real-time quantitative PCR (RQ-PCR) and reverse transcription PCR (RT-PCR), and next-generation sequencing (NGS) are increasingly being integrated into clinical practice to assess treatment response, stratify relapse risk, and inform personalized therapy decisions.
In April 2026, Ultima Genomics announced key milestones for its ppmSeq technology with data presented across six abstracts at the 2026 AACR Annual Meeting in San Diego. The program featured initial TRACERx MRD data showcasing ppmSeq performance relative to ultrasensitive bespoke panels, with data from collaborators including LabCorp and DELFI Diagnostics. The technology provides low single-digit parts-per-million sensitivity with a simple, scalable, and distributable whole genome workflow.
Also in April 2026, Quest Diagnostics announced that City of Hope is implementing Haystack MRD, a highly accurate circulating-tumor DNA (ctDNA) MRD test, for clinical trial participants with solid tumor cancers including breast, colorectal, ovarian, and prostate cancer. The multi-year research program is expected to serve approximately 500 patients with thousands of longitudinal measurements from fourteen City of Hope sites across the United States.
Emerging Therapies in the MRD Pipeline
The MRD pipeline includes a diverse range of therapeutic approaches, including monoclonal antibodies, CAR T-cell therapies, bispecific antibodies, and gene-modified cell therapies. Increasing emphasis is being placed on combination regimens that integrate MRD-directed therapies with standard-of-care treatments to achieve deeper and more durable responses.
AMB-066, developed by AmMax Bio (搜索), is a potent monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R (搜索)), designed to modulate the tumor microenvironment and enhance immune-mediated clearance of residual cancer cells. The therapy is being evaluated for colorectal cancer-associated MRD and has been tested in approximately 200 patients and healthy subjects across multiple clinical trials for other indications, demonstrating a favorable safety and tolerability profile. AMB-066 is currently in Phase II clinical development.
Glofitamab, from Genentech, is a bispecific antibody that targets CD20 (搜索) on B cells and CD3 (搜索) on T cells, facilitating T-cell-mediated cytotoxicity against malignant B cells. It represents a promising approach in hematologic malignancies, particularly in achieving MRD negativity.
PRGN-3006, developed by Precigen Inc (搜索), is an investigational CAR T-cell therapy designed to target specific tumor antigens and eliminate residual malignant cells. This next-generation cell therapy leverages advanced gene engineering technologies to enhance efficacy and persistence.
Clinical Trial Activity and Collaborations
The MRD pipeline is characterized by increasing clinical trial activity across global markets. In February 2026, TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced the submission to the FDA of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TTX-MC138. The study will be conducted within the PRE-I-SPY program and represents the program's first expansion into colorectal cancer.
Strategic collaborations and licensing agreements are accelerating pipeline development, with partnerships between industry players and academic institutions playing a crucial role in advancing MRD research.
Market Drivers and Future Outlook
The growth of the MRD pipeline is driven by several factors, including the increasing prevalence of cancer, rising awareness of MRD as a prognostic marker, and advancements in diagnostic technologies. The shift toward personalized medicine and targeted therapies is further fueling innovation. However, challenges remain, including variability in MRD detection methods, lack of standardized thresholds, and complexities in integrating MRD into clinical decision-making. The high cost of advanced diagnostics and therapies may also limit accessibility in certain regions.
Looking ahead, the MRD landscape is expected to witness substantial growth, driven by continued investment in research and development, integration of artificial intelligence in diagnostics, and expansion of immunotherapy approaches. The adoption of MRD as a surrogate endpoint in clinical trials is likely to accelerate regulatory approvals and commercialization of new therapies.